CY1125083T1 - Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου - Google Patents

Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου

Info

Publication number
CY1125083T1
CY1125083T1 CY20221100217T CY221100217T CY1125083T1 CY 1125083 T1 CY1125083 T1 CY 1125083T1 CY 20221100217 T CY20221100217 T CY 20221100217T CY 221100217 T CY221100217 T CY 221100217T CY 1125083 T1 CY1125083 T1 CY 1125083T1
Authority
CY
Cyprus
Prior art keywords
thiazol
substituted
yluminum
benzamides
compounds
Prior art date
Application number
CY20221100217T
Other languages
English (en)
Inventor
Adam Davenport
Nico BRÄUER
Oliver Martin Fischer
Andrea Rotgeri
Antje Rottmann
Ioana NEAGOE
Jens Nagel
Anne-Marie GODINHO-COELHO
Jürgen KLAR
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52015966&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125083(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CY1125083T1 publication Critical patent/CY1125083T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις υποκατεστημένου βενζαμιδίου 1,3-θειαζολ-2-υλίου του γενικού τύπου (I), όπως περιγράφονται και ορίζονται στην παρούσα, σε φαρμακευτικές συνθέσεις και συνδυασμούς που περιλαμβάνουν τις εν λόγω ενώσεις και στη χρήση των εν λόγω ενώσεων για την παρασκευή μίας φαρμακευτικής σύνθεσης για τη θεραπευτική αντιμετώπιση ή προφύλαξη από μία πάθηση, συγκεκριμένα από νευρογενή διαταραχή, ως ένας μοναδικός παράγοντας ή σε συνδυασμό με άλλα δραστικά συστατικά.
CY20221100217T 2014-12-09 2022-03-15 Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου CY1125083T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196954 2014-12-09
EP15804824.9A EP3230281B1 (en) 2014-12-09 2015-12-07 1,3-thiazol-2-yl substituted benzamides
PCT/EP2015/078765 WO2016091776A1 (en) 2014-12-09 2015-12-07 1,3-thiazol-2-yl substituted benzamides

Publications (1)

Publication Number Publication Date
CY1125083T1 true CY1125083T1 (el) 2023-06-09

Family

ID=52015966

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20211100750T CY1124486T1 (el) 2014-12-09 2021-08-20 Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
CY20221100217T CY1125083T1 (el) 2014-12-09 2022-03-15 Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20211100750T CY1124486T1 (el) 2014-12-09 2021-08-20 Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου

Country Status (41)

Country Link
US (5) US10174016B2 (el)
EP (2) EP3587417B9 (el)
JP (2) JP6544665B2 (el)
KR (2) KR20230098368A (el)
CN (2) CN107207507B (el)
AR (2) AR102948A1 (el)
AU (1) AU2015359626B2 (el)
BR (1) BR112017012327B1 (el)
CA (1) CA2969952A1 (el)
CL (1) CL2017001488A1 (el)
CO (1) CO2017005742A2 (el)
CR (2) CR20170242A (el)
CU (1) CU24411B1 (el)
CY (2) CY1124486T1 (el)
DK (2) DK3230281T3 (el)
DO (2) DOP2017000137A (el)
EA (2) EA032312B1 (el)
EC (1) ECSP17036253A (el)
ES (2) ES2908822T3 (el)
HR (2) HRP20220371T1 (el)
HU (2) HUE055290T2 (el)
IL (6) IL252665B (el)
JO (1) JOP20150301B1 (el)
LT (2) LT3230281T (el)
MA (2) MA50674B1 (el)
MX (2) MX2017007658A (el)
MY (1) MY192690A (el)
NI (1) NI201700073A (el)
PE (2) PE20220253A1 (el)
PH (1) PH12017501079A1 (el)
PL (2) PL3587417T3 (el)
PT (2) PT3587417T (el)
RS (2) RS62227B1 (el)
SG (2) SG10202012274RA (el)
SI (2) SI3587417T1 (el)
SV (1) SV2017005461A (el)
TN (1) TN2017000244A1 (el)
TW (2) TWI716371B (el)
UA (1) UA120382C2 (el)
UY (1) UY36422A (el)
WO (1) WO2016091776A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62227B1 (sr) * 2014-12-09 2021-09-30 Bayer Ag 1,3-tiazol-2-il supstituisani benzamidi
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN106588785A (zh) * 2016-12-02 2017-04-26 山东吉田香料股份有限公司 一种乙酰基吡嗪的制备方法
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
JOP20200286A1 (ar) 2018-05-15 2020-11-09 Bayer Ag بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
SG11202011018PA (en) * 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
CA3115649A1 (en) 2018-10-05 2020-04-09 Shionogi & Co., Ltd. Medicament for the treatment of chronic cough
KR20210074315A (ko) * 2018-10-10 2021-06-21 벨루스 헬스 코프 인크. P2x3 길항제를 사용한 소양증의 치료
AU2020228760A1 (en) * 2019-02-25 2021-09-23 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment with P2X3 modulators
CN113661165A (zh) * 2019-04-05 2021-11-16 先正达农作物保护股份公司 杀有害生物活性的二嗪-酰胺化合物
MA55587A (fr) * 2019-04-11 2022-02-16 Syngenta Crop Protection Ag Composés diazine-amide à action pesticide
AU2020281924A1 (en) 2019-05-31 2021-12-16 Chiesi Farmaceutici S.P.A. Pyridopyrimidines derivatives as P2X3 inhibitors
CN113891745B (zh) 2019-05-31 2024-05-07 奇斯药制品公司 作为p2x3抑制剂的氨基喹唑啉衍生物
EP3757103A1 (en) 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN113082023B (zh) * 2019-12-23 2024-03-01 武汉朗来科技发展有限公司 P2x3抑制剂和p2x4抑制剂的药物组合及其应用
WO2021238834A1 (zh) * 2020-05-25 2021-12-02 中国医药研究开发中心有限公司 芳甲酰胺类化合物及其制备方法和医药用途
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
IL301667A (en) 2020-09-30 2023-05-01 Humanwell Healthcare Group Co Ltd Benzamide compound and its use
WO2022112493A1 (en) 2020-11-27 2022-06-02 Chiesi Farmaceutici S.P.A. Phthalazine derivatives as p2x3 inhibitors
KR20230113536A (ko) 2020-11-27 2023-07-31 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 (아자)퀴놀린 4-아민 유도체
CA3196333A1 (en) 2020-11-27 2022-06-02 Claudio FIORELLI Amino quinazoline derivatives as p2x3 inhibitors
WO2022253943A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide
WO2022253945A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
TW202404965A (zh) * 2022-03-29 2024-02-01 大陸商人福醫藥集團股份公司 Ｐ２ｘ３抑制劑化合物及其鹽、多晶型和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
ES2604542T3 (es) 2006-06-29 2017-03-07 F. Hoffmann-La Roche Ag Arilamidas con sustitución tetrazol
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
BRPI0718714B8 (pt) * 2006-11-09 2021-05-25 Hoffmann La Roche arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
PL2139334T3 (pl) 2007-04-17 2013-11-29 Evotec Ag Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
US20090317360A1 (en) * 2007-06-12 2009-12-24 Genelabs Technologies, Inc. Anti-viral inhibitors and methods of use
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
WO2009058299A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3 receptor antagonists for treatment of pain
DK2234976T3 (da) 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
ES2570628T3 (es) 2007-12-17 2016-05-19 Hoffmann La Roche Nuevas arilamidas con sustitución imidazol
JP5456691B2 (ja) 2007-12-17 2014-04-02 エフ．ホフマン−ラ ロシュ アーゲー テトラゾール置換されたアリールアミド誘導体ならびにｐ２ｘ３及び／又はｐ２ｘ２／３プリン作動性受容体アンタゴニストとしてのその使用
AU2008337660B2 (en) 2007-12-17 2014-02-06 F. Hoffmann-La Roche Ag Triazole-substituted arylamide derivatives and their use as P2X3 and /or P2X2/3 purinergic receptor antagonists
CA2715835C (en) * 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
CA2737038A1 (en) 2008-09-18 2010-03-25 Evotec Ag Amide compounds, compositions and uses thereof
EP2860178B1 (en) * 2008-10-31 2021-01-13 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
WO2010069794A1 (en) 2008-12-16 2010-06-24 F. Hoffmann-La Roche Ag Thiadiazole-substituted arylamides
ES2450891T3 (es) 2009-06-22 2014-03-25 F. Hoffmann-La Roche Ag Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3
SG176640A1 (en) 2009-06-22 2012-01-30 Hoffmann La Roche Novel oxazolone and pyrrolidinone-substituted arylamides
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
US9562041B2 (en) * 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
TR201807602T4 (tr) 2013-01-31 2018-06-21 Neomed Inst İmidazopiridin bileşikleri ve bunların kullanımları.
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
RS62227B1 (sr) * 2014-12-09 2021-09-30 Bayer Ag 1,3-tiazol-2-il supstituisani benzamidi
JOP20200286A1 (ar) 2018-05-15 2020-11-09 Bayer Ag بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
SG11202011018PA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3757103A1 (en) 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases

Also Published As

Publication number Publication date
TW201629053A (zh) 2016-08-16
EP3230281A1 (en) 2017-10-18
US11142523B2 (en) 2021-10-12
DOP2017000137A (es) 2017-07-31
CU20170077A7 (es) 2017-11-07
TWI716371B (zh) 2021-01-21
CU24411B1 (es) 2019-05-03
EP3230281B1 (en) 2021-05-26
NZ733108A (en) 2022-03-25
SV2017005461A (es) 2018-04-30
IL283979A (en) 2021-07-29
CN107207507A (zh) 2017-09-26
MA50674A (fr) 2021-03-31
PL3587417T3 (pl) 2022-06-13
IL269661A (en) 2019-11-28
CN110256418B (zh) 2023-01-20
AU2015359626A1 (en) 2017-06-29
ECSP17036253A (es) 2017-06-30
MA41135B1 (fr) 2021-10-29
US10174016B2 (en) 2019-01-08
DK3230281T3 (da) 2021-08-16
PT3230281T (pt) 2021-08-19
PH12017501079A1 (en) 2017-10-18
TW202130637A (zh) 2021-08-16
KR20230098368A (ko) 2023-07-03
IL283979B (en) 2022-04-01
CN107207507B (zh) 2020-11-06
BR112017012327A2 (pt) 2018-02-27
BR112017012327A8 (pt) 2021-02-23
SG10202012274RA (en) 2021-01-28
IL269468A (en) 2019-11-28
IL275183B (en) 2021-06-30
EP3587417A1 (en) 2020-01-01
HRP20211002T1 (hr) 2021-09-17
PL3230281T3 (pl) 2021-12-13
EA034273B1 (ru) 2020-01-23
DK3587417T3 (da) 2022-03-28
IL269467A (en) 2019-11-28
IL269661B (en) 2020-07-30
EP3587417B9 (en) 2022-03-30
JP6544665B2 (ja) 2019-07-17
US10472354B2 (en) 2019-11-12
HUE058009T2 (hu) 2022-06-28
DOP2018000182A (es) 2018-09-15
WO2016091776A1 (en) 2016-06-16
IL275183A (en) 2020-07-30
RS63014B1 (sr) 2022-04-29
IL252665B (en) 2019-10-31
SI3230281T1 (sl) 2021-08-31
ES2908822T3 (es) 2022-05-04
US20190185466A1 (en) 2019-06-20
CL2017001488A1 (es) 2018-02-23
CR20210108A (es) 2021-04-27
JOP20150301B1 (ar) 2023-09-17
MA50674B1 (fr) 2022-11-30
EA201891120A1 (ru) 2018-10-31
RS62227B1 (sr) 2021-09-30
UA120382C2 (uk) 2019-11-25
JP2019059742A (ja) 2019-04-18
IL252665A0 (en) 2017-08-31
BR112017012327B1 (pt) 2023-04-11
SG11201704717VA (en) 2017-08-30
PE20180227A1 (es) 2018-01-31
KR102548799B1 (ko) 2023-06-27
JP6647371B2 (ja) 2020-02-14
US20180093980A1 (en) 2018-04-05
IL269468B (en) 2020-06-30
LT3230281T (lt) 2021-07-12
KR20170093203A (ko) 2017-08-14
TWI780562B (zh) 2022-10-11
AR102948A1 (es) 2017-04-05
HRP20220371T1 (hr) 2022-05-13
CY1124486T1 (el) 2022-07-22
CR20170242A (es) 2018-02-02
CA2969952A1 (en) 2016-06-16
HUE055290T2 (hu) 2021-11-29
PT3587417T (pt) 2022-03-16
PE20220253A1 (es) 2022-02-16
EP3587417B1 (en) 2022-01-05
MY192690A (en) 2022-09-01
CO2017005742A2 (es) 2017-09-20
LT3587417T (lt) 2022-02-10
US20200131169A1 (en) 2020-04-30
SI3587417T1 (sl) 2022-04-29
US10202369B2 (en) 2019-02-12
NI201700073A (es) 2017-10-24
JP2017537122A (ja) 2017-12-14
MX2017007658A (es) 2018-08-01
CN110256418A (zh) 2019-09-20
EA032312B1 (ru) 2019-05-31
EA201791261A1 (ru) 2017-12-29
MX2020005909A (es) 2021-10-28
AR119761A2 (es) 2022-01-12
UY36422A (es) 2016-06-30
US20230053411A1 (en) 2023-02-23
ES2882952T3 (es) 2021-12-03
US20180118731A1 (en) 2018-05-03
AU2015359626B2 (en) 2020-07-23
IL269467B (en) 2020-08-31
TN2017000244A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
CY1125083T1 (el) Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UY35492A (es) Compuestos novedosos
DOP2016000253A (es) Nuevos compuestos
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.